Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Drug Briefing: Lenacapavir


    Query Drug:LenacapavirQuery Time:2024-06-24 11:06:36*** Disclaimer *** The information provided here is sourced from resources such as, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
  • Groundbreaking HIV Prevention Drug Shows 100% Efficacy in Phase 3 Trial


    A recent Phase 3 clinical trial (NCT04994509), dubbed "PURPOSE 1," has yielded promising results for a new HIV prevention drug, potentially revolutionizing the field of HIV prophylaxis. The study, conducted by Gilead Sciences, evaluated the safety and efficacy of Lenacapavir, a novel long-acting HIV Read More
  • Market Expansion: Dapagliflozin Receives FDA Approval for Treating Type 2 Diabetes in Children


    AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3 Read More
  • The Complement System: A Frontier in Drug Development


    The complement system has long been recognized as a crucial component of the innate immune system, acting as the first line of defense against invading pathogens. However, recent advancements in understanding this intricate network have unveiled its multifaceted roles in various physiological proces Read More
  • Tirzepatide Approved by NMPA for Type II Diabetes


    On May 21st, the Chinese National Medical Products Administration (NMPA) approved Tirzepatide (brand name Mounjaro), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Lilly, for the improvement of glycemic control in adults wi Read More
  • Opportunities for API Manufacturers in the Expanding Ruxolitinib Market


    Ruxolitinib, a groundbreaking product of Incyte Corp, has demonstrated an impressive evolution in the pharmaceutical market. Its strategic journey from a niche treatment for rare diseases to a versatile solution for more common dermatological conditions not only emphasizes the strategic significance Read More
  • Scaling the Everest of Pharma Synthesis: A Deep Dive into Eribulin's Journey


    As one steps into the realm of pharmaceutical discovery, the name Eribulin, also known as Halaven, rings a powerful note. First approved in 2010 by Eisai, this non-peptide drug, intricate in its synthesis and impressive in the magnitude of its medical impact, has been nothing short of groundbreaking Read More
  • Cancer, radiopharma & RDCs


    Market potential of radiopharma & RDCsRDCs are currently being developed for cancer. According to the WHO IARC, in 2022, the five most common cancers resulted in 19,956,054 new cases and 9,736,520 deaths. It is estimated that by 2050, the incidence of all cancers will reach 35.3 million. Consequentl Read More
  • Seizing the Opportunity in the CGRP Targeting Drugs Market


    The global pharmaceutical landscape is witnessing a remarkable surge in the development and approval of drugs targeting trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor, especially for treating migraine, a debilitating neurological disorder affecting a substantial adult Read More
  • Total 3 pages  Go to Page
  • Go